The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Role of polymorphic fc gamma receptor II/III  in the efficacy of cetuximab in KRAS-NRAS-BRAF-PI3K mutated.
Jesus Garcia-Foncillas
No relevant relationships to disclose
Javier Rodriguez
No relevant relationships to disclose
Valentina Boni
No relevant relationships to disclose
Iosu Sola
No relevant relationships to disclose
Beatriz Honorato
No relevant relationships to disclose
Ruth Zarate
No relevant relationships to disclose
Eva Bandres
No relevant relationships to disclose